ClinicalTrials.gg
CompletedNCT04974047RATIONALE-213Updated Dec 1, 2025Results posted

Study of Tislelizumab in Participants With Resectable Esophageal Squamous Cell Carcinoma

A Phase 2 interventional study of Tislelizumab and Paclitaxel in Resectable Esophageal Squamous Cell Carcinoma, sponsored by BeiGene. Completed at 8 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-01.

Sponsored by BeiGene · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
70
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 23 studies testing tislelizumab in Esophageal Squamous Cell Carcinoma — 13 open to participants now, 15 under way, 1 of them phase 3. tislelizumab · Esophageal Squamous Cell Carcinoma.

Enrollment
10th of 23
70 · median 50
Started
2021
with 1 other
Phase 2
14 of 23
8 open now
Registered
5th of 23
by date
Lead sponsor
5 of 23
BeiGene

Among the 23 studies testing tislelizumab in Esophageal Squamous Cell Carcinoma, this one is the 10th largest by enrollment, is one of 2 that started in 2021, is one of 14 in phase 2, and was the 5th registered.

Esophageal Squamous Cell Carcinoma

678 studies on the registry are indexed under Esophageal Squamous Cell Carcinoma; 269 are open to participants now.

Browse Esophageal Squamous Cell Carcinoma studies →

Open to participants now

13 of the 23 studies testing tislelizumab in Esophageal Squamous Cell Carcinoma are open now, in 4 countries. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 13 open studies →

About tislelizumab

tislelizumab: first FDA approval 2024 (TEVIMBRA), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 180 Esophageal Squamous Cell Carcinoma studies recruiting now, 83 (46%) set no upper age limit and 76 (42%) stop at 75 or younger; 3 take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies testing tislelizumab in Esophageal Squamous Cell Carcinoma, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the pathological complete response (pCR) in participants receiving tislelizumab plus chemotherapy/chemoradiotherapy as neoadjuvant treatment.

Read the detailed description

This study enrolled participants with esophageal squamous cell carcinoma who were eligible to have their tumor removed by surgery (also called surgical resection). The treatment phase of the study included the following:

  • Induction therapy, in which participants received 1 cycle of chemotherapy;
  • Neoadjuvant therapy (neoadjuvant refers to treatment that occurs before surgery, which can make the tumor easier to remove). In this study participants received neoadjuvant therapy based on their response to induction therapy. Response to induction therapy was assessed using the maximum standardized uptake value (SUVmax) measured using a Positron Emission Tomography (PET) scan. The SUV number refers to the level of brightness on the PET scan which reflects metabolic activity; increased metabolic activity can indicate cancerous growth.

    • Participants with a decrease in SUVmax of 35% or more after induction therapy received neoadjuvant treatment with tislelizumab plus chemotherapy.
    • Participants with a decrease in SUVmax less than 35% after induction therapy received neoadjuvant treatment with tislelizumab plus chemotherapy and radiotherapy.
  • Surgery to remove the remaining tumor (resection) was to occur 4-6 weeks after completion of neoadjuvant treatment.

After surgery participants were followed until death, lost to follow-up, withdrawal of consent, or until the study was completed

03

Conditions studied

  • Resectable Esophageal Squamous Cell Carcinoma

Keywords

  • Tislelizumab
  • PET
  • Chemotherapy
  • Chemoradiotherapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Performance Status of 0 or 1.
  • confirmed esophageal squamous cell carcinoma (ESCC).
  • Stage cT1-2N+M0 and cT3NanyM0 (per The American Joint Committee on Cancer 8th Edition).
  • Evaluation by the investigator to confirm eligibility for an R0 resection with curative intent.
  • Adequate hematologic and organ function, defined by protocol-specified laboratory test results obtained within 14 days before first dose.

Key Exclusion Criteria:

  • Ineligible for treatment with any of the chemotherapy doublets of protocol-specified chemotherapy.
  • Any prior therapy for current ESCC, including agents, chemotherapy, radiotherapy, targeted therapy agents, or prior therapy with an anti-programmed cell death protein-1, anti-programmed cell death protein ligand-1, anti-programmed cell death protein ligand-2, or any other antibody or drug specifically targeting T-Cell co-stimulation or checkpoint pathways.
  • History of fistula due to primary tumor invasion.
  • Participants with high risk of fistula or sign of perforation evaluated by investigator.
  • Any condition requiring systemic treatment with either (> 10 mg daily prednisone or equivalent) or other medications within 14 days before first dose.

    * Adrenal replacement steroid (dose ≤ 10 mg daily of prednisone or equivalent) and topical, ocular, intra-articular, intranasal, or inhaled corticosteroid with minimal systemic absorption, and short course (≤ 7 days) of corticosteroid prescribed prophylactically or for the treatment of a non- condition are permitted.

  • Active autoimmune diseases or history of autoimmune diseases that may relapse.

    * Controlled Type I diabetes, hypothyroidism only requiring hormone replacement, controlled celiac disease, skin diseases (such as vitiligo, psoriasis, or alopecia) not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are permitted to enroll.

  • History of interstitial lung disease, non-infectious pneumonitis or uncontrolled diseases including pulmonary fibrosis, acute lung diseases.
  • With infections requiring systemic antibacterial, antifungal, or antiviral therapy, including tuberculosis infection.

    • Severe infections within 4 weeks before first dose, including but not limited to hospitalization for complications of infection, bacteremia, or severe pneumonia.
    • Receive therapeutic oral or intravenous antibiotics within 2 weeks before first dose.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
70 participants (actual)

Study arms

  • Experimental
    Cohort A (Responder)

    Participants received induction therapy of one 21-day cycle with cisplatin and paclitaxel administered on Day 1. Following the induction phase, participants with a decrease in positron emission tomography (PET) Standardized Uptake Value (SUV)max ≥ 35% then received neoadjuvant therapy consisting of 200 mg tislelizumab on Day 1 of each 21-day cycle for 3 cycles and chemotherapy doublet (cisplatin + paclitaxel) for 2 cycles. After neoadjuvant treatment, participants were assessed for disease resectability and underwent surgical resection of the tumor approximately 4 to 6 weeks later.

    Drug: Tislelizumab · Drug: Paclitaxel · Drug: Cisplatin · Procedure: Surgical resection

  • Experimental
    Cohort B (Non-responder)

    Participants received induction therapy of one 21-day cycle with cisplatin and paclitaxel administered on Day 1. Following the induction phase, participants with a decrease in PET SUVmax \< 35% then received neoadjuvant therapy consisting of 200 mg tislelizumab on Day 1 of each 21-day cycle for 3 cycles and investigator-chosen chemotherapy doublet (paclitaxel + cisplatin or 5-fluorouracil + cisplatin) for 2 cycles plus concurrent radiotherapy. After neoadjuvant treatment, participants were assessed for disease resectability and underwent surgical resection of the tumor approximately 4 to 6 weeks later.

    Drug: Tislelizumab · Drug: Paclitaxel · Drug: Cisplatin · Drug: 5-fluorouracil · Radiation: Radiotherapy · Procedure: Surgical resection

Interventions

  • Administered intravenously on Day 1 of each 21-Day Cycle.

    Also known as: BGB-A317

  • 135 mg/m\^2 administered intravenously on Day 1 of each 21-Day Cycle.

  • 80 mg/m\^2 administered intravenously on Day 1 of each 21-Day Cycle.

  • 1000 mg/m\^2 administered intravenously over Day 1 through 4 of each 21-Day Cycle.

  • RadiationRadiotherapy

    40 grays/20 fractions

  • ProcedureSurgical resection

    Performed as indicated in the treatment arm.

06

What researchers measure

Primary outcomes

  1. Pathological Complete Response (pCR) Rate

    The pCR rate was defined as the percentage of participants with absence of residual tumor in the resected primary tumor and all resected lymph nodes after completion of neoadjuvant treatment. pCR rates were assessed by a pathologist at each site.

    Time frame: pCR was determined from samples taken during surgery; surgery occurred 4-6 weeks after the last dose of chemotherapy, approximately Day 71-86

Secondary outcomes

  1. R0 Resection Rate

    Defined as the percentage of participants with R0 resection. R0 resection refers to a surgical procedure where the entire tumor is completely removed with no evidence of residual cancer tissue at the surgical margins.

    Time frame: Resection was planned to occur 4-6 weeks after the last dose of chemotherapy, approximately Day 71-86

  2. 1-year/3-year Disease-free Survival (DFS) Rate

    The DFS rate is defined as the percentage of participants free from disease events at 1 year and 3 years after the first date of no disease (R0 resection as surgery outcome). Disease events include local or distant recurrence or death due to any cause. The DFS rate was analyzed only for participants who underwent R0 resection. Disease-free rates were estimated using the Kaplan-Meier method with 95% confidence intervals estimated using the Greenwood formula.

    Time frame: 1 year and 3 years after surgery

  3. 1-year/3-year Event-free Survival (EFS) Rate

    The EFS rate is defined as the percentage of participants free from EFS events at 1 year and 3 years after the first dose. The EFS events include progression of disease that precludes definitive surgery, local or distant recurrence, or death due to any cause. Event-free rates were estimated using the Kaplan-Meier method with 95% confidence intervals estimated using the Greenwood formula.

    Time frame: 1 year and 3 years after first dose date

  4. Objective Response Rate (ORR)

    The ORR is defined as the percentage of participants who have a complete response or partial response before surgery as assessed by the investigator per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) in all participants with measurable disease at baseline. Tumor response was assessed by computed tomography (CT) or magnetic resonance imaging (MRI) of the neck, chest, and abdomen. Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or nontarget) must have reduction in short axis to \< 10 mm. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

    Time frame: ORR was assessed prior to surgery, Day 71 to 86

  5. Number Of Participants Experiencing Treatment-Emergent Adverse Events

    Immune-mediated AEs were reported until 90 days after the last dose of tislelizumab

    Time frame: From the first dose of study drug up to 30 days after last dose of any component of treatment or surgery or the initiation of subsequent anticancer therapy, whichever occurred first. Up to approximately 9 months.

07

Results

Posted Dec 1, 2025

Participant flow

This study was conducted at 8 study centers in China.

Participant flow — Overall Study
MilestoneCohort A (Responder)Cohort B (Non-responder)
Started3040
Surgical resection performed2133
Completed00
Not completed3040
Withdrew: Sponsor ended study2022
Withdrew: Death817
Withdrew: Lost to follow-up20
Withdrew: Withdrawal by subject01

Outcome measures

PrimaryPathological Complete Response (pCR) Rate

The pCR rate was defined as the percentage of participants with absence of residual tumor in the resected primary tumor and all resected lymph nodes after completion of neoadjuvant treatment. pCR rates were assessed by a pathologist at each site.

Time frame:
pCR was determined from samples taken during surgery; surgery occurred 4-6 weeks after the last dose of chemotherapy, approximately Day 71-86
Reported as:
Number · percentage of participants
Pathological Complete Response (pCR) Rate
percentage of participantsCohort A (Responder)Cohort B (Non-responder)
Pathological Complete Response (pCR) Rate30.0 (11.9 to 54.3)34.4 (18.6 to 53.2)
SecondaryR0 Resection Rate

Defined as the percentage of participants with R0 resection. R0 resection refers to a surgical procedure where the entire tumor is completely removed with no evidence of residual cancer tissue at the surgical margins.

Time frame:
Resection was planned to occur 4-6 weeks after the last dose of chemotherapy, approximately Day 71-86
Reported as:
Number · percentage of participants
R0 Resection Rate
percentage of participantsCohort A (Responder)Cohort B (Non-responder)
R0 Resection Rate95.090.6
Secondary1-year/3-year Disease-free Survival (DFS) Rate

The DFS rate is defined as the percentage of participants free from disease events at 1 year and 3 years after the first date of no disease (R0 resection as surgery outcome). Disease events include local or distant recurrence or death due to any cause. The DFS rate was analyzed only for participants who underwent R0 resection. Disease-free rates were estimated using the Kaplan-Meier method with 95% confidence intervals estimated using the Greenwood formula.

Time frame:
1 year and 3 years after surgery
Reported as:
Number · percentage of participants
1-year/3-year Disease-free Survival (DFS) Rate
percentage of participantsCohort A (Responder)Cohort B (Non-responder)
1 Year79.0 (47.9 to 92.7)74.2 (53.3 to 86.8)
Secondary1-year/3-year Event-free Survival (EFS) Rate

The EFS rate is defined as the percentage of participants free from EFS events at 1 year and 3 years after the first dose. The EFS events include progression of disease that precludes definitive surgery, local or distant recurrence, or death due to any cause. Event-free rates were estimated using the Kaplan-Meier method with 95% confidence intervals estimated using the Greenwood formula.

Time frame:
1 year and 3 years after first dose date
Reported as:
Number · percentage of participants
1-year/3-year Event-free Survival (EFS) Rate
percentage of participantsCohort A (Responder)Cohort B (Non-responder)
1 Year87.1 (64.3 to 95.8)67.8 (48.3 to 81.2)
3 Years75.5 (49.8 to 89.3)59.9 (40.0 to 75.1)
SecondaryObjective Response Rate (ORR)

The ORR is defined as the percentage of participants who have a complete response or partial response before surgery as assessed by the investigator per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) in all participants with measurable disease at baseline. Tumor response was assessed by computed tomography (CT) or magnetic resonance imaging (MRI) of the neck, chest, and abdomen. Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or nontarget) must have reduction in short axis to \< 10 mm. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

Time frame:
ORR was assessed prior to surgery, Day 71 to 86
Reported as:
Number · percentage of participants
Objective Response Rate (ORR)
percentage of participantsCohort A (Responder)Cohort B (Non-responder)
Objective Response Rate (ORR)71.4 (47.8 to 88.7)42.4 (25.5 to 60.8)
SecondaryNumber Of Participants Experiencing Treatment-Emergent Adverse Events

Immune-mediated AEs were reported until 90 days after the last dose of tislelizumab

Time frame:
From the first dose of study drug up to 30 days after last dose of any component of treatment or surgery or the initiation of subsequent anticancer therapy, whichever occurred first. Up to approximately 9 months.
Reported as:
Count of participants · Participants
Number Of Participants Experiencing Treatment-Emergent Adverse Events
ParticipantsCohort A (Responder)Cohort B (Non-responder)
Number Of Participants Experiencing Treatment-Emergent Adverse Events3039

Adverse events

Collected over All-cause-mortality: From first dose until the end of study; maximum time on study follow-up was 37.3 months. AEs: From the first dose of study drug up to 30 days after the last treatment (any component of combination treatment or surgery, whichever is last) or the initiation of subsequent anticancer therapy, whichever occurred first. Immune-mediated AEs were reported until 90 days after the last dose of tislelizumab, up to approximately 9 months.. Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort A (Responder)8/30 (26.7%)8/30 (26.7%)30/30 (100%)
Cohort B (Non-responder)17/40 (42.5%)12/40 (30%)39/40 (97.5%)
Most frequent serious events
Showing 10 of 20
Most frequent serious events
EventCohort A (Responder)Cohort B (Non-responder)
PneumoniaInfections and infestations0/302/40
Neutrophil count decreasedInvestigations1/302/40
Acute coronary syndromeCardiac disorders1/300/40
Immune-mediated myocarditisCardiac disorders1/300/40
Abdominal painGastrointestinal disorders1/300/40
DysphagiaGastrointestinal disorders1/301/40
Upper gastrointestinal haemorrhageGastrointestinal disorders1/300/40
FatigueGeneral disorders1/300/40
Gastrointestinal anastomotic leakInjury, poisoning and procedural complications1/300/40
White blood cell count decreasedInvestigations1/301/40
Most frequent other events
Showing 10 of 91
Most frequent other events
EventCohort A (Responder)Cohort B (Non-responder)
White blood cell count decreasedInvestigations19/3035/40
Neutrophil count decreasedInvestigations19/3034/40
AnaemiaBlood and lymphatic system disorders21/3032/40
VomitingGastrointestinal disorders10/3016/40
HypoalbuminaemiaMetabolism and nutrition disorders4/3016/40
NauseaGastrointestinal disorders11/3014/40
Platelet count decreasedInvestigations7/3012/40
HypokalaemiaMetabolism and nutrition disorders6/3011/40
Weight decreasedInvestigations3/3010/40
HyperglycaemiaMetabolism and nutrition disorders3/3010/40

Baseline characteristics

Age, Continuous
Age, Continuous(years)Cohort A (Responder)Cohort B (Non-responder)Total
Mean64.6 ± 8.1663.1 ± 7.0663.7 ± 7.53
Sex: Female, Male
Sex: Female, Male(Participants)Cohort A (Responder)Cohort B (Non-responder)Total
Female628
Male243862
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Cohort A (Responder)Cohort B (Non-responder)Total
Hispanic or Latino000
Not Hispanic or Latino304070
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Cohort A (Responder)Cohort B (Non-responder)Total
American Indian or Alaska Native000
Asian304070
Native Hawaiian or Other Pacific Islander000
Black or African American000
White000
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)Cohort A (Responder)Cohort B (Non-responder)Total
China304070
08

Study locations

8 sites
  • Anhui Provincial Hospital
    Hefei, Anhui 230000, China
  • Fujian Medical University Union Hospital
    Fuzhou, Fujian 350001, China
  • The Fourth Hospital of Hebei Medical University
    Shijiazhuang, Hebei 050011, China
  • Union Hospital of Tongji Medical College, Huazhong University of Science and Technology
    Wuhan, Hubei 430022, China
  • Tangdu Hospital
    Xi'an, Shaanxi 710038, China
  • Affiliated Zhongshan Hospital of Fudan University
    Shanghai, Shanghai Municipality 200032, China
  • West China Hospital, Sichuan University
    Chengdu, Sichuan 610041, China
  • Tianjin Medical University Cancer Institute and Hospital
    Tianjin, Tianjin Municipality 300060, China
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — BeiGene shares data on completed studies responsibly and provides qualified scientific and medical researchers access to data and supporting documentation for clinical trials in dossiers for medicines and indications after submission and approval in the United States, China, and Europe. Clinical trials supporting subsequent local approvals, new indications, or combination products are eligible for sharing once corresponding regulatory approvals are achieved. BeiGene shares data only when permitted by applicable data privacy and security laws and regulations, when it is feasible to do so without compromising the privacy of study participants, and other considerations. Qualified researchers with appropriate competencies who are engaged in novel scientific research may submit a request for participant-level data with a research proposal for BeiGene review. Research teams must include a biostatistician and sign a Data Sharing Agreement prior to receiving access to clinical trial data.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: See plan description

Access criteria: See plan description

Data sharing details ↗ · beigene.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2021 to primary completion in Apr 2023, 20 months.

Results were first posted in Dec 2025, 2 years 7 months after primary completion.

Of 173 phase 2 interventional studies under Esophageal Squamous Cell Carcinoma, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 52. This study's 20 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 3, 2021
First posted
Jul 23, 2021
StartActual
Aug 17, 2021
Primary completionActual
Apr 17, 2023
CompletionActual
Oct 25, 2024
Results first posted
Dec 1, 2025
Last update
Dec 1, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 1, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04974047
Lead sponsor
BeiGene
Responsible party
Sponsor
First posted
Jul 23, 2021
Start date
Aug 17, 2021
Primary completion
Apr 17, 2023
Completion
Oct 25, 2024
Results posted
Dec 1, 2025
Last update
Dec 1, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tislelizumab

Start the discussion